Arcutis Biotherapeutics (ARQT) executive compensation, 2026 proxy

Todd Franklin Watanabe, President and Chief Executive Officer, was paid $7.2M in 2025, up 96% from $3.7M the year before. The CEO-to-median-employee pay ratio was 28:1, on median employee pay of $262,613.

Filed
April 21, 2026
Annual meeting
June 5, 2026
Pay year
2025
Named executives
6
CEO total pay
$7.2M+96% vs prior year
CEO to median employee
28:1median $262,613
CEO pay in equity
82%$5.9M in awards
CEO Salary
$713,333Base salary for fiscal 2025
CEO Stock Awards
$2,067,190Grant date fair value
CEO Option Awards
$3,848,958Grant date fair value
CEO Non-Equity Incentive
$579,584Performance-based cash incentive earned
Median Employee Pay
$262,613Annual total compensation

How Watanabe was paid

$7.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary10%Stock awards29%Option awards53%Non-equity incentive8%All other compensation0%

Named executive officers

ExecutiveTotal
Todd Franklin WatanabePresident and Chief Executive Officer$7,223,065
Latha VairavanChief Financial Officer$1,924,780
Patrick E. Burnett, M.D., Ph.D.Chief Medical Officer$3,016,508
L. Todd EdwardsChief Commercial Officer$3,030,337
Masaru Matsuda, J.D.Chief Legal Officer$2,118,203
David TopperFormer Chief Financial Officer$1,946,733

What changed and why

  • $7.2MCEO total compensation increased to $7,223,065 in 2025 from $3,689,491 in 2024.
  • Stock and option awards represented the largest portion of the CEO total compensation.
  • Latha Vairavan was promoted to Chief Financial Officer effective May 6, 2025.
  • David Topper separated from the Company as Chief Financial Officer on May 15, 2025.
  • The pay ratio of CEO to median employee compensation was 28 to 1.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.